Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET).
Timothy J. Hobday
No relevant relationships to disclose
Rui Qin
No relevant relationships to disclose
Malcolm J. Moore
No relevant relationships to disclose
Diane Lauren Reidy
No relevant relationships to disclose
Jonathan R. Strosberg
Honoraria - Genentech
Hedy Lee Kindler
No relevant relationships to disclose
Manisha H. Shah
No relevant relationships to disclose
Heinz-Josef Lenz
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Research Funding - Genentech
Andreas Kaubisch
No relevant relationships to disclose
Helen X. Chen
No relevant relationships to disclose
Charles Erlichman
No relevant relationships to disclose